α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study

[1]  A. Viúdez,et al.  Stellate cells, a point of light in the dark night of pancreatic cancer , 2014, British Journal of Cancer.

[2]  R. Muschel,et al.  The stromal compartments in pancreatic cancer: are there any therapeutic targets? , 2014, Cancer letters.

[3]  A. Maitra,et al.  A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA). , 2014 .

[4]  P. Möller,et al.  S3-Leitlinie zum exokrinen Pankreaskarzinom , 2013, Zeitschrift für Gastroenterologie.

[5]  A. Masamune,et al.  Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer , 2013, Front. Physiol..

[6]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[7]  A. Hinke,et al.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. , 2013, JAMA.

[8]  H. Toyokawa,et al.  Activation of alpha-smooth muscle actin-positive myofibroblast-like cells after chemotherapy with gemcitabine in a rat orthotopic pancreatic cancer model , 2013, Journal of hepato-biliary-pancreatic sciences.

[9]  山尾 順.  Activation of alpha-smooth muscle actin-positive myofibroblast-like cells after chemotherapy with gemcitabine in a rat orthotopic pancreatic cancer model , 2013 .

[10]  H. Friess,et al.  [S3-guideline exocrine pancreatic cancer]. , 2013, Zeitschrift fur Gastroenterologie.

[11]  Derek S. Chan,et al.  The Pancreas Cancer Microenvironment , 2012, Clinical Cancer Research.

[12]  Alexander A. Fingerle,et al.  The role of stroma in pancreatic cancer: diagnostic and therapeutic implications , 2012, Nature Reviews Gastroenterology &Hepatology.

[13]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Friess,et al.  StellaTUM: current consensus and discussion on pancreatic stellate cell research , 2011, Gut.

[15]  Lin Cui,et al.  &agr;-Smooth Muscle Actin Expressing Stroma Promotes an Aggressive Tumor Biology in Pancreatic Ductal Adenocarcinoma , 2010, Pancreas.

[16]  A. Delany.  Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma , 2010, Cancer biology & therapy.

[17]  K. Garber.  Stromal depletion goes on trial in pancreatic cancer. , 2010, Journal of the National Cancer Institute.

[18]  Helmut Friess,et al.  The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  D. Goldstein,et al.  Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance. , 2008, Cancer research.

[20]  C. Iacobuzio-Donahue,et al.  Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Peter Neuhaus,et al.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. , 2007, JAMA.

[22]  R. Lunevicius,et al.  Clinicopathological significance of fibrotic capsule formation around liver metastasis from colorectal cancer , 2001, Journal of Cancer Research and Clinical Oncology.